Patient adherence is the focus of a new project launched by the Innovative Medicines Initiative (IMI) and led by Pfizer.

Queen’s University Belfast has entered into a collaboration and licensing agreement with Ipsen to research, develop, manufacture and commercialise FLIP inhibitors.